Congenital Bleeding Disorder: Clinical Trials

4 completed. 4 Phase 4.

By phase and status

Phase	Trials	Status
Phase 4	4	Completed 4

Follow Congenital Bleeding Disorder: new trials by email Literature Review of Congenital Bleeding Disorder trials Research Report on Congenital Bleeding Disorder

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period turoctocog alfa - Congenital Bleeding Disorder, Haemophilia A	Phase 4	Completed	Novo Nordisk A/S	60	2018-03-01	2020-04-17
High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors activated recombinant human factor VII - Congenital Bleeding Disorder, Haemophilia A With Inhibitors	Phase 4	Completed	Novo Nordisk A/S	24	2002-11-01	2017-01-12
Trial of NovoSeven® in Haemophilia - Joint Bleeds eptacog alfa (activated), Feiba VH - Congenital Bleeding Disorder, Haemophilia A With Inhibitors	Phase 4	Completed	Novo Nordisk A/S	42	2001-09-01	2017-01-12
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery activated recombinant human factor VII, factor IX, factor VIII - Congenital Bleeding Disorder, Haemophilia A With Inhibitors	Phase 4	Completed	Novo Nordisk A/S	36	1998-04-01	2023-12-29

Narrower conditions

Hemophilia A (1)

Broader conditions

Blood Coagulation Disorders (1)  ·  Blood Coagulation Disorders, Inherited (1)  ·  Coagulation Protein Disorders (1)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Genetic Diseases, Inborn (1)  ·  Hematologic Diseases (1)  ·  Hemic and Lymphatic Diseases (1)  ·  Hemorrhagic Disorders (1)

Interventions

Factor IX (1)  ·  Factor VII (1)  ·  Factor VIII (1)  ·  anti-inhibitor coagulant complex (1)  ·  recombinant factor VIII N8 (1)

Sponsors

Novo Nordisk A/S (4)

Countries

United States (2)  ·  France (1)  ·  Hungary (1)  ·  India (1)  ·  Israel (1)  ·  Poland (1)  ·  Spain (1)  ·  Turkey (Türkiye) (1)  ·  United Kingdom (1)

Results publications

PMID 16601828, PMID 17938794, PMID 18081834

NIH funding

2017 (1)